R-CHOEP-14 regimen
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: Rituximab-Cyclophosphamide-Hydroxydaunorubicin-Oncovin-Etoposide-Prednisone regimen
Overview
Overview
R-CHOEP-14 regimen refers to a two-week regimen consisting of rituximab,cyclophosphamide, doxorubicin (hydroxydaunorubicin, vincristine (Oncovin), etoposide, and prednisone used to treat diffuse large B-cell lymphoma.[1]
Regimen
Regimen
RRituximab
CCyclophosphamide
HDoxorubicin (Hydroxydaunomycin)
OVincristine (Oncovin)
EEtoposide
PPrednisone
References
References
- ↑ 1.0 1.1 Gang AO, Strøm C, Pedersen M, d’Amore F, Pedersen LM, Bukh A; et al. (2012). “R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group”. Ann Oncol. 23 (1): 147–53. doi:10.1093/annonc/mdr058. PMID 21460380.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH